{
  "slug": "adaptive-biotechnologies",
  "name": "Adaptive Biotechnologies",
  "description": "Adaptive Biotechnologies is a commercial-stage company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its proprietary immune medicine platform reveals and translates the genetic code of the immune system to develop better diagnostics and therapeutics.",
  "url": "https://optimly.ai/brand/adaptive-biotechnologies",
  "logoUrl": "",
  "baiScore": 88,
  "archetype": "Challenger",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [
    {
      "slug": "10x-genomics",
      "name": "10x Genomics"
    },
    {
      "slug": "guardant-health",
      "name": "Guardant Health"
    },
    {
      "slug": "natera",
      "name": "Natera"
    }
  ],
  "inboundCompetitors": [
    {
      "slug": "personalis-next-personal",
      "name": "Personalis (NeXT Personal)"
    }
  ],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-04-10T17:05:35.278+00:00",
  "verifiedVitals": {
    "website": "https://www.adaptivebiotech.com",
    "founded": "2009",
    "headquarters": "Seattle, WA",
    "pricing_model": "Usage-based (clinical tests) and Enterprise/Custom (drug discovery partnerships)",
    "core_products": "clonoSEQ (MRD testing), immunoSEQ (research service), Drug Discovery (partnerships)",
    "key_differentiator": "The only company with an FDA-cleared NGS assay to detect minimal residual disease (MRD) at the sensitivity of one-in-a-million cells.",
    "target_markets": "Oncologists, academic researchers, and biopharmaceutical companies",
    "employee_count": "Approx. 850",
    "funding_stage": "Public (NASDAQ:ADPT)",
    "subcategory": "Molecular Diagnostics & Immunosequencing"
  },
  "intentTags": {
    "problemIntents": [
      "Standard Flow Cytometry/qPCR: Using traditional flow cytometry or specialized PCR to track disease, though with lower sensitivity than NGS.",
      "Standard Clinical Monitoring: Continuing current clinical monitoring without minimal residual disease (MRD) testing, risking missing early relapse.",
      "Specialized CRO Services: Hiring specialized labs or CROs to develop custom assays for specific clinical trials."
    ],
    "solutionIntents": [
      "What is MRD testing in leukemia?",
      "NGS immune repertoire sequencing providers",
      "Best liquid biopsy for solid tumors",
      "T-cell receptor mapping technology",
      "Is clonoSEQ FDA approved?"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1776207289317
}